Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 26,200 shares at $103.64 ($2.7M) on 2024-04-03, disclosed to the SEC on 2024-04-05.
Scheduled sale ($2.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $97.47 | 200 | $19K | 0.7% |
| 2 | $99.40 | 1,499 | $149K | 5.6% |
| 3 | $99.40 | 1,499 | $149K | 5.6% |
| 4 | $100.66 | 3,167 | $319K | 12.0% |
| 5 | $100.66 | 3,167 | $319K | 12.0% |
| 6 | $101.33 | 3,832 |
| $388K |
| 14.6% |
| 7 | $101.33 | 3,832 | $388K | 14.6% |
| 8 | $102.64 | 3,500 | $359K | 13.5% |
| 9 | $103.64 | 2,702 | $280K | 10.5% |
| 10 | $103.64 | 2,702 | $280K | 10.5% |
| 11 | $104.15 | 100 | $10K | 0.4% |
| Total | $101.58 avg | 26,200 | $2.7M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |